Niiden nivelten sisäisen traneksaamihapon käytön tulevaisuuden tutkimus valinnaisessa lonkan artroplastiassa

This prospective, parallel-group clinical study was conducted at the First Department of Orthopaedic Surgery, St. Anne's University Hospital and the Faculty of Medicine, Masaryk University, Brno, Czech Republic. Patient recruitment and prospective data collection were performed from January 1, 2023, to December 31, 2025.

The study was designed to evaluate whether the addition of intra-articular tranexamic acid (TXA) to standard intravenous TXA administration improves perioperative blood-management outcomes in patients undergoing elective primary total hip arthroplasty (THA). Eligible patients undergoing elective THA were allocated before surgery to one of two parallel treatment groups. Patients undergoing arthroplasty for traumatic indications were excluded.

All procedures were performed under spinal anesthesia using an anterolateral Watson-Jones approach. All patients received 1 g of intravenous TXA before skin incision. In the intravenous-only group, no additional local TXA was administered. In the combined-treatment group, patients received an additional 2 g of TXA diluted in 10 mL of saline, applied intra-articularly around the implanted prosthesis after definitive component implantation, completion of surgical haemostasis, and drying of the operative field, immediately before closure of the fascia lata.

Standardized perioperative management was used in both groups. Meticulous electrocautery haemostasis was performed, and a single Redon suction drain was placed in the operated hip and removed 24 hours after surgery. Patients received perioperative thromboprophylaxis with low-molecular-weight heparin according to the institutional protocol.

The principal objective of the study was to assess the effect of additional intra-articular TXA on perioperative blood loss and transfusion requirements. Perioperative outcomes included postoperative drainage volume, changes in haemoglobin concentration, red blood cell transfusion requirements, and length of hospital stay. Haemoglobin concentration was recorded preoperatively, on the day of surgery, and on postoperative day 1. Changes in haemoglobin concentration were evaluated from the preoperative value to the day of surgery and from the preoperative value to postoperative day 1. Red blood cell transfusion requirements were assessed both as the proportion of patients requiring transfusion and according to the number of transfused units.

Postoperative wound-related and medical complications were also prospectively evaluated. These included persistent wound leakage, requirement for single-use negative-pressure wound therapy, debridement with antibiotics and implant retention (DAIR), implant explantation, and clinically diagnosed thromboembolic complications. Surgical wounds were routinely assessed during the postoperative period, and persistent or progressive wound complications were treated according to the institutional protocol.

The study was intended to determine whether combined intravenous and intra-articular administration of TXA provides additional haemostatic benefit compared with intravenous TXA alone while maintaining an acceptable postoperative safety profile in patients undergoing elective primary THA.